Antimicrobial Partnerships Arietis Pharma is a Boston-based biotech focused on novel antimicrobial agents targeting Staphylococcus aureus and Helicobacter pylori. As a small company with alliances, it is well positioned for licensing, co-development, or exclusive regional partnerships to accelerate its pipeline and create value for partners and investors.

Sterile Manufacturing Their pipeline centers on sterilizing antibiotics, creating a clear need for GMP manufacturing and fill-finish capabilities. This opens opportunities for contract manufacturing organizations to provide early-to-clinical scale-up, process development, and supply agreements as Arietis advances toward clinical testing.

Clinical Development Arietis is in discovery and development and would benefit from clinical development and regulatory support, including IND planning, CMC documentation, and early-phase trial management. Position business development efforts around CRO partnerships, regulatory consulting, and outsourcing to de-risk program progression.

Strategic Alliances Arietis has forged productive alliances; there is an opportunity to secure strategic funding or co-development partnerships with venture funds or corporate investors. Propose milestone-based licensing deals, joint development programs, and broader collaborations to scale the antimicrobial pipeline.

Hospital Market With a focus on hospital-associated infections and gastric ulcers, Arietis can target hospital systems, antimicrobial stewardship programs, and GPOs in the US market. Proposals could include pilot programs, access to hospital networks for real-world data, and early access partnerships for novel antibiotics.